What is Kodiak Sciences?
Kodiak Sciences Inc., formerly Oligasis, LLC, is a clinical-stage biopharmaceutical firm established in 2015 and headquartered in Palo Alto, California. The company is dedicated to the research, development, and commercialization of innovative treatments for debilitating retinal diseases. Its primary focus is on tarcocimab tedromer (KSI-301), an antibody biopolymer targeting vascular endothelial growth factor (VEGF), which is currently undergoing Phase IIb/III clinical trials for wet age-related macular degeneration (AMD). Additionally, Kodiak Sciences is advancing preclinical candidates such as KSI-501, a bispecific conjugate designed to target pro-inflammatory cytokines like interleukin-6 (IL-6) and VEGF, aiming to address a range of retinal inflammatory conditions.
How much funding has Kodiak Sciences raised?
Kodiak Sciences has raised a total of $476.4M across 6 funding rounds:
Other Financing Round
$1.8M
Series B
$34M
Debt
$33M
Stock Offering
$90M
Stock Offering
$317.4M
Debt
$150K
Other Financing Round (2009): $1.8M with participation from Undisclosed
Series B (2016): $34M led by Undisclosed
Debt (2018): $33M supported by ArrowMark Partners and Perceptive Advisors
Stock Issuance/Offering (2018): $90M featuring Undisclosed
Stock Issuance/Offering (2019): $317.4M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in Kodiak Sciences
ArrowMark Partners
ArrowMark Partners is an investment firm that has participated in funding rounds for Kodiak Sciences. Their involvement suggests a strategic interest in the company's therapeutic development.
Perceptive Advisors
Perceptive Advisors is a New York-based investment firm established in 1999, managing approximately $7 billion in assets. They specialize in funding innovative healthcare and life sciences technologies, aligning with Kodiak Sciences' focus on biopharmaceutical advancements.
Undisclosed Investors
What's next for Kodiak Sciences?
The recent major strategic investment in Kodiak Sciences signals a pivotal moment for the company, likely enabling accelerated clinical development and potential commercialization efforts for its lead candidate, tarcocimab tedromer. This infusion of capital is expected to bolster its research pipeline, including the advancement of its preclinical assets. The company's focus on addressing significant unmet needs in retinal disease treatment positions it for substantial growth and impact within the biopharmaceutical industry.
See full Kodiak Sciences company page
